Roche’s most advanced obesity drug allowed patients in a Phase 2 trial who took it for nearly a year to lose 18.3% of their weight after correcting for placebo, the Swiss pharma
Takeda ‘anticipated’ Medicare negotiations for top seller Entyvio
Incoming Takeda CEO Julie Kim says the drugmaker “anticipated” this week’s selection of Entyvio for Medicare negotiations. But for now, the company isn’t ready to


